Back to results
US 2012/0238576 A1Published application
Triazine Derivatives and their Therapeutical Applications
AssigneeCalifornia Capital Equity, LLC
InventorsChunlin Tao, Qinwei Wang, Laxman Nallan, Tulay Polat, Lukasz Koroniak, Neil Desai
Life of this patent
Estimating the term…
Abstract
The present invention comprises inter alia compounds as shown in formula (I) or a pharmaceutically acceptable salt thereof.
Claims29
A compound of the formula
- or a pharmaceutically acceptable salt thereof, wherein:
- A, B, W is selected from S, O, NR4, CR4 or L-R3;
- R4 is independently selected from hydrogen or an optionally substituted C1-4 aliphatic group.
- R1 represents hydrogen, halogen, hydroxy, amino, cyano, alkyl, cycloalkyl, alkenyl, alkynyl, alkylthio, aryl, arylalkyl, heterocyclic, heteroaryl, heterocycloalkyl, alkylsulfonyl, alkoxycarbonyl and alkylcarbonyl.
- R2 is selected from:
- (i) amino, alkyl amino, aryl amino, heteroaryl amino;
- (ii) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl;
- (iii) heterocyclic, heteroaryl;
- and
- (iv) groups of the formula (Ia):
- wherein:
- R5 represents hydrogen, C1-C4 alkyl, oxo;
- X is CH, when R6 is hydrogen;
- or X—R6 is O;
- or X is N, R6 represents groups of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 aryl or heteroaryl, (C3-C7cycloalkyl)C1-C4alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio, C2-C6 alkanoyl, C1-C6 alkoxycarbonyl, C2-C6 alkanoyloxy, mono- and di-(C3-C8 cycloalkyl)aminoC0-C4alkyl, (4- to 7-membered heterocycle)C0-C4alkyl, C1-C6 alkylsulfonyl, mono- and di-(C1-C6 alkyl) sulfonamido, and mono- and di-(C1-C6alkyl)aminocarbonyl, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, —COOH and oxo;
- L represents O, S, SO, CO, SO2, CO2, NR4, (CH2)m, m=0-3, CONR4, NR4CO, NR4SO2, SO2NR4, NR4CO2, NR4COR4, NR4SO2NR4, NR4NR4, OCONR4, C(R4)2CONR4, NR4COC(R4), C(R4)2SO, C(R4)2SO2, C(R4)2SO2NR4, C(R4)2NR4, C(R4)2NR4CO, C(R4)2NR4CO2, C(R4)═NNR4, C(R4)═N—O, C(R4)2NR4NR4, C(R4)2NR4SO2NR4, C(R4)2NR4CONR4, O(CH2)p, S(CH2)p, p=1-3, or (CH2)q0, or (CH2)qS, q=1-3;
- R3 is selected from:
- (i) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl;
- (ii) heterocyclic,
- (iii) Ar,
- Ar represents heteroaryl or aryl, each of which is substituted with from 0 to 4 substituents independently chosen from:
- (1) halogen, hydroxy, amino, cyano, —COOH, —SO2NH2, oxo, nitro and alkoxycarbonyl;
- and
- (2) C1-C6 alkyl, C1-C6alkoxy, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C6 alkanoyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, mono- and di-(C1-C6alkyl)amino, C1-C6 alkylsulfonyl, mono- and di-(C1-C6alkyl) sulfonamido and mono- and di-(C1-C6alkyl)aminocarbonyl;
- phenylC0-C4alkyl and (4- to 7-membered heterocycle)-C0-C4alkyl, each of which is substituted with from 0 to 4 secondary substituents independently chosen from halogen, hydroxy, cyano, oxo, imino, C1-C4alkyl, C1-C4alkoxy and C1-C4haloalkyl;
- K is selected from:
- i) absence;
- ii) O, S, SO, SO2;
- iii) (CH2)m, m=0-3, O(CH2)p, p=1-3, (CH2)qO, q=1-3,
- iv) NR7;
- and
- R7 represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, alkylthio, aryl, arylalkyl.
29 more elements
A compound selected from the group consisting of:
A compound of the formula
- or a pharmaceutically acceptable salt thereof, wherein:
- Y is selected from —OR4, —NR4R5, and -Q-R3;
- Q is selected from cycloalkyl and heterocycloalkyl, each of which is optionally substituted with C1-C6 alkyl or oxo;
- R3 is selected from H, C1-C6 alkyl, C1-C6 alkyl-R6, aryl, and heteroaryl, each of which is optionally substituted with C1-C6 alkyl, halo, trifluoromethyl, or oxo;
- R4 and R5 are each independently selected from H, C1-C6 alkyl-R6, aryl, and heteroaryl;
- R6 is selected from hydroxy, cyano, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —NH2, mono(C1-C6)alkylamino, di(C1-C6)alkylamino, and C1-C6 alkoxy;
- X is —NH—Ar1—R1;
- Ar1 is selected from aryl and heteroaryl, each of which is optionally substituted with C1-C6 alkyl or halo;
- R1 is selected from —(CH2)nC(O)NHW, —CH2C(O)NHAr1, and —NH2;
- n=0, 1;
- W is selected from C1-C6 alkyl, cycloalkyl, and —(CH2)Ar1;
- Z is selected from H, C1-C6 alkyl, aryl, and heteroaryl.
9 more elements
A compound of the formula
- or a pharmaceutically acceptable salt thereof, wherein:
- Y is selected from —OR4, —NR4R5, and -Q-R3;
- Q is selected from morpholinyl, piperazinyl and piperidinyl;
- R3 is selected from H, C1-C6 alkyl, hydroxy(C1-C6)alkyl, cyano(C1-C6)alkyl, pyridinylmethyl, pyridinyl, phenyl, trifluoromethylphenyl, and oxo;
- R4 and R5 are each independently selected from H, C1-C6 alkyl-R6, and phenyl;
- R6 is selected from hydroxy, morpholinyl, di(C1-C6)alkylamino, imidazolyl, and C1-C6 alkoxy;
- X is —NH—Ar1—R1;
- Ar1 is selected from thiazolyl, oxazolyl, oxadiazolyl, methyl-imidazolyl, pyrazolyl;
- R1 is selected from —(CH2)nC(O)NHW and —NH2;
- n=0, 1;
- W is selected from C1-C6 alkyl and —(CH2)nPh optionally substituted with C1-C6 alkyl or halo;
- Z is selected from H, C1-C6 alkyl, and phenyl.
9 more elements
A compound of the formula
- or a pharmaceutically acceptable salt thereof, wherein:
- Y is selected from —OR4, —NR4R5, and -Q-R3;
- Q is selected from morpholinyl, piperazinyl and piperidinyl;
- R3 is selected from H, C1-C6 alkyl, hydroxy(C1-C6)alkyl, cyano(C1-C6)alkyl, pyridinylmethyl, pyridinyl, phenyl, trifluoromethylphenyl, and oxo;
- R4 and R5 are each independently selected from H, C1-C6 alkyl-R6, and phenyl;
- R6 is selected from hydroxy, morpholinyl, di(C1-C6)alkylamino, imidazolyl, and C1-C6 alkoxy;
- X is —NH—Ar1—R′;
- Ar1 is selected from thiazolyl, oxazolyl, oxadiazolyl, methyl-imidazolyl, pyrazolyl;
- R1 is selected from —(CH2)nC(O)NHW, —CH2C(O)NHAr2, and —NH2;
- n=0, 1;
- W is selected from C1-C6 alkyl, cycloalkyl, and —(CH2)Ar2;
- Ar2 is phenyl, optionally substituted with C1-C6 alkyl or halo;
- Z is selected from H, C1-C6 alkyl, and phenyl.
10 more elements
Dependencies are inferred from the claim text.